CD106+ P-MSC

According to our research, P-MSCs can inhibit excessive immune response, restore the balance of immune function, and thus can be used for treatment of immune rejection after hematopoietic stem cell transplantation, and other autoimmune diseases such as Crohn's disease, lupus erythematodes, scleroderma, etc.

P-MSCs can secrete several kinds of angiogenic factors, including vascular growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factor (bFGF), transforming growth factor (TGF- beta) and insulin growth factor (IGF-1).

Professor Zhongzhao HAN’s team for the first time identified an active subset of placental mesenchymal stem cells that is CD106 positive mesenchymal stem cells, and applied for a patent in China.

CD106, also known as vascular cell adhesion molecule 1, plays a key role in regulating immune function and promoting angiogenesis of mesenchymal stem cells. For the first time, our team found that the proportion of CD106 positive cells in placental mesenchymal stem cells accounts for about 70%, far above the rate of CD106 positive cells in other types of mesenchymal stem cells. Further studies have shown that placental CD106 positive mesenchymal stem cells have a stronger angiogenesis activity compared with other mesenchymal stem cells.

CD106 positive placental mesenchymal stem cells were pre-mixed with a special gel called Matrigel by our research team. With the extending of incubation time, P-MSC proliferated and differentiated into blood-vessels-like tissues. Compared with CD106 negative mesenchymal stem cells, CD106 positive mesenchymal stem cells reconstituted more abundant neovascularization on the Matrigel.